Agenus’ BOT/BAL Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward Registration with FDA Alignment on Phase 3
July 7, 2025
Diffusion Pharmaceuticals Reports Positive Trend in Oxygenation from TCOM Trial
June 30, 2021
Related Post
-
-
Immix Biopharma Announces Accelerated NEXICART-2 Clinical Trial Progress in relapsed/refractory AL Amyloidosis
July 7, 2025
-
Hemostemix’s VesCell Sales are Legal in Florida as it Pivots to Allow Non-FDA Approved Stem Cell Treatments!
July 2, 2025
-
bluebird bio Announces Completion of Acquisition by Carlyle and SK Capital
June 2, 2025